Rinvoq ER 45 MG tablet UU 28S
Ended Awarded Last action
- Contract number
- SPE2DR26F95K3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,938
Award facts
- Contract value 100% obligated
- $12,938.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,938.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units). This firm fixed price, non-set-aside delivery order was awarded on December 16, 2025, with an ultimate completion date of December 17, 2025. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, representing a specialty pharmaceutical product within the military healthcare supply chain.
This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceuticals and medical supplies to support military healthcare programs worldwide. AmerisourceBergen, as a major pharmaceutical distributor and critical federal medical procurement vendor, maintains an extensive portfolio of competitively awarded delivery orders with the Defense Logistics Agency, demonstrating its capability to fulfill diverse federal medical supply requirements across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F95K3?
SPE2DR26F95K3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26F95K3 worth?
The government has obligated $12,938 on SPE2DR26F95K3.
Is contract SPE2DR26F95K3 an order under another contract?
Yes. SPE2DR26F95K3 is a delivery order under SPE2DR25D3505, an indefinite delivery contract.
Was contract SPE2DR26F95K3 competed?
The extent of competition for SPE2DR26F95K3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award